SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial.

Karg, M V

SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial. [electronic resource] - Cardiovascular diabetology 01 2018 - 5 p. digital

Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

1475-2840

10.1186/s12933-017-0654-z doi


Aged
Benzhydryl Compounds--adverse effects
Blood Glucose--drug effects
Blood Pressure--drug effects
Cross-Over Studies
Diabetes Mellitus, Type 2--blood
Double-Blind Method
Female
Germany
Glucosides--adverse effects
Humans
Male
Middle Aged
Muscle, Skeletal--drug effects
Prospective Studies
Skin--drug effects
Sodium--metabolism
Sodium-Glucose Transporter 2--drug effects
Sodium-Glucose Transporter 2 Inhibitors--adverse effects
Time Factors
Treatment Outcome